R&D US vs EU: How can Europe translate home-grown innovation int... We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States.
News Cancer biotech Nouscom adds €120m, and other financings A €120m Series D for Swiss biotech Nouscom will support trials of a Lynch syndrome vaccine, with Soufflé, Estuary, and Microbiotica also raising cash.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.